Schizophrenia Medication non-adherence Schizophrenia Medication Adherence Antipsychotics Medication Community Mental Health
Conditions
Interventions
Participants received the Individualized Medication Adherence Program (IMAP) in addition to standard care provided by the primary healthcare centers. IMAP is an individualized behavioral intervention
s needs and included psychoeducation, medication management, collaborative problem-solving, family involvement, behavioral skill-building, relapse prevention, and motivational interviewing-informed co
Experimental Behavioral,No Intervention No treatment
Experimental group,Control group
Sponsors
Lia Endriyani
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older. 2. A documented diagnosis of schizophrenia according to the DSM-5 or ICD-10 criteria, as recorded in the participant's medical record. 3. Receiving healthcare services in a primary care setting and prescribed at least one oral antipsychotic medication. 4. Have a history of relapse or multiple relapses, indicating an increased risk of medication non-adherence. 5. Have a history of medication non-adherence as assessed using the Medication Adherence Rating Scale (MARS). 6. Have not been hospitalized within the 3 months preceding enrollment. 7. Able to understand, communicate, read, and write in Indonesian. 8. Willing to participate in the study and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. A documented diagnosis of another psychiatric disorder in addition to schizophrenia. 2. Have a history of neurological or medical conditions associated with cognitive impairment, such as traumatic brain injury or dementia, that could interfere with study participation. 3. No documented history of psychiatric hospitalization following the diagnosis of schizophrenia. 4. Being physically restrained (e.g., by shackling or chaining) at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Medication Adherence Baseline (T0), post-intervention (T1), and 3-month follow-up (T2). Medication Adherence Rating Scale (MARS-10) | — |
Secondary
| Measure | Time frame |
|---|---|
| Psychotic Symptoms Baseline (T0), post-intervention (T1), and 3-month follow-up (T2). Positive and Negative Syndrome Scale (PANSS) | — |
Countries
Indonesia
Contacts
Public ContactLia Endriyani
Universitas Alma Ata
Outcome results
None listed